Next Article in Journal
Microbial Biofilms and Antibiofilm Agents 2.0
Next Article in Special Issue
Prenatal Exposure to Delta-9-tetrahydrocannabinol (THC) Alters the Expression of miR-122-5p and Its Target Igf1r in the Adult Rat Ovary
Previous Article in Journal
The Problem of Wound Healing in Diabetes—From Molecular Pathways to the Design of an Animal Model
Previous Article in Special Issue
Targeting the Achilles’ Heel of Multidrug-Resistant Staphylococcus aureus by the Endocannabinoid Anandamide

The Origin and Biomedical Relevance of Cannabigerol

Department of Analytical Chemistry, Medical University of Bialystok, A. Mickiewicza 2D, 15-222 Bialystok, Poland
Author to whom correspondence should be addressed.
Academic Editor: Timna Naftali
Int. J. Mol. Sci. 2022, 23(14), 7929;
Received: 30 June 2022 / Revised: 16 July 2022 / Accepted: 16 July 2022 / Published: 19 July 2022
(This article belongs to the Special Issue New Insight into Cannabinoid Effects)
The constant search for new pharmacologically active compounds, especially those that do not exhibit toxic effects, intensifies the interest in plant-based ingredients and their potential use in pharmacotherapy. One of the plants that has great therapeutic potential is Cannabis sativa L., a source of the psychoactive Δ9-tetrahydrocannabinol (Δ9-THC), namely cannabidiol (CBD), which exhibits antioxidant and anti-inflammatory properties, and cannabigerol (CBG)—a biologically active compound that is present in much smaller quantities. CBG is generated during the non-enzymatic decarboxylation of cannabigerolic acid, a key compound in the process of biosynthesis of phytocannabinoids and consequently the precursor to various phytocannabinoids. By interacting with G-protein-coupled receptors, CBG exhibits a wide range of biological activities, inter alia, anti-inflammatory, antibacterial and antifungal activities, regulation of the redox balance, and neuromodulatory effects. Due to the wide spectrum of biological activities, CBG seems to be a very promising compound to be used in the treatment of diseases that require multidirectional pharmacotherapy. Moreover, it is suggested that due to the relatively rapid metabolism of cannabigerol, determination of the concentration of the phytocannabinoid in blood or oral fluid can be used to determine cannabis use. Therefore, it seems obvious that new therapeutic approaches using CBG can be expected. View Full-Text
Keywords: Cannabis sativa L.; cannabigerol-type group; cannabigerol; biosynthesis; biological activity; pharmacokinetics Cannabis sativa L.; cannabigerol-type group; cannabigerol; biosynthesis; biological activity; pharmacokinetics
Show Figures

Figure 1

MDPI and ACS Style

Jastrząb, A.; Jarocka-Karpowicz, I.; Skrzydlewska, E. The Origin and Biomedical Relevance of Cannabigerol. Int. J. Mol. Sci. 2022, 23, 7929.

AMA Style

Jastrząb A, Jarocka-Karpowicz I, Skrzydlewska E. The Origin and Biomedical Relevance of Cannabigerol. International Journal of Molecular Sciences. 2022; 23(14):7929.

Chicago/Turabian Style

Jastrząb, Anna, Iwona Jarocka-Karpowicz, and Elżbieta Skrzydlewska. 2022. "The Origin and Biomedical Relevance of Cannabigerol" International Journal of Molecular Sciences 23, no. 14: 7929.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop